Polymyxin B
- Generic Name
- Polymyxin B
- Brand Names
- Casporyn HC, Cortisporin, Dioptrol, Diosporin, Diphen, Maxitrol, Neo-polycin, Neo-polycin HC, Neosporin Ointment, Neosporin Plus Maximum Strength, Neosporin Plus Maximum Strength Cream, Neosporin Solution, Polycin-B, Polysporin, Polytrim, Procomycin, Statrol, Triple Antibiotic
- Drug Type
- Small Molecule
- Chemical Formula
- C56H98N16O13
- CAS Number
- 1404-26-8
- Unique Ingredient Identifier
- J2VZ07J96K
- Background
Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.
- Indication
Polymyxin B is indicated for the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa.
- Associated Conditions
- Acute Otitis Media (AOM), Bacteremia caused by Enterobacter aerogenes, Bacterial Conjunctivitis, Bacterial Infections, Chronic Otitis Media, Escherichia urinary tract infection, Klebsiella bacteraemia, Meningitis caused by Haemophilus influenzae, Meningitis, Bacterial, Ocular Inflammation, Otitis Externa, Otorrhoea, Superficial ocular infections of the conjunctiva caused by susceptible bacteria, Superficial ocular infections of the cornea caused by susceptible bacteria, Urinary Tract Infection, Ocular bacterial infections
Intraventricular Administration of Intracranial Infections Caused by （Carbapenem-resistant Gram-negative Bacilli）CRGNB
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 222
- Registration Number
- NCT06595979
- Locations
- 🇨🇳
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
A Pharmacokinetic Study of Polymyxin B in Healthy Subjects and Subjects With Renal Insufficiency
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- TTY Biopharm
- Target Recruit Count
- 22
- Registration Number
- NCT05359627
- Locations
- 🇨🇳
Shin Kong Memorial Wu Ho-Su Hospital, Taipei, Taiwan
The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae
- Conditions
- Antibiotic Resistant Infection
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Shanghai 10th People's Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03950544
- Locations
- 🇨🇳
Shanghai 10th people's hospital, Shanghai, Shanghai, China
Tacrolimus for Malar Edema
- Conditions
- Edema Face
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 100
- Registration Number
- NCT03715387
- Locations
- 🇨🇦
Vancouver Plastic Surgery Center, Vancouver, British Columbia, Canada
Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- University of Puerto Rico
- Target Recruit Count
- 40
- Registration Number
- NCT03159078
- Locations
- 🇵🇷
Trauma Hospital, San Juan, Puerto Rico
Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 100
- Registration Number
- NCT02328183
- Locations
- 🇹🇭
Siriraj hospital, Bangkok, Thailand
Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria
- Conditions
- BacteremiaVentilator-associated PneumoniaHealthcare-associated Pneumonia
- Interventions
- Drug: Polymyxin B + Doripenem
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Tan Tock Seng Hospital
- Registration Number
- NCT02134106
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬Singapore General Hospital, Singapore, Singapore
Effect of Nitroglycerin Ointment on Mastectomy Flap Necrosis
- Conditions
- Mastectomy Flap Necrosis
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 154
- Registration Number
- NCT01608880
- Locations
- 🇨🇦
Mount Saint Joseph Hospital, Vancouver, British Columbia, Canada
🇨🇦Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦University of British Columbia Hospital, Vancouver, British Columbia, Canada
Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections
- Conditions
- Blood Stream InfectionsSkin Diseases, Infectious
- Interventions
- Other: Petroleum Jelly
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Fraser Health
- Registration Number
- NCT00990392
- Locations
- 🇨🇦
Royal Columbian Hospital, New Westminster, British Columbia, Canada
Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 20
- Registration Number
- NCT00695578
- Locations
- 🇺🇸
Wake Forest University Health Sciences Dermatology, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.